{"id":"ptv-r-obv-dsv","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Elevated bilirubin"}]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PTV/r/OBV/DSV combines paritaprevir (protease inhibitor), ritonavir (booster), ombitasvir (NS5A inhibitor), and dasabuvir (NS5B inhibitor) to target multiple steps of the HCV replication cycle. The combination achieves high cure rates across multiple HCV genotypes by preventing viral protein synthesis and RNA replication.","oneSentence":"This is a fixed-dose combination of hepatitis C virus (HCV) protease and NS5A inhibitors that blocks viral replication by inhibiting essential nonstructural proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:16.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1)"}]},"trialDetails":[{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT03050905","phase":"PHASE4","title":"Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-06-22","conditions":"HCV Coinfection","enrollment":7},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":"Hepatitis Viruses","enrollment":46},{"nctId":"NCT03710252","phase":"PHASE4","title":"A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","status":"COMPLETED","sponsor":"American Research Corporation","startDate":"2016-03","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Viekirax/Exviera"],"phase":"marketed","status":"active","brandName":"PTV/r/OBV/DSV","genericName":"PTV/r/OBV/DSV","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of hepatitis C virus (HCV) protease and NS5A inhibitors that blocks viral replication by inhibiting essential nonstructural proteins. Used for Chronic hepatitis C virus infection (genotype 1).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}